CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 87 enrolled
Drug / intervention
Losartan +2 moredrug
Likely dose
Losartan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01637623
NCT01637623Phase 2Completed
CompareCT.gov

Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea

University of Wisconsin, Madison·interventional·Posted Jul 11, 2012·Updated Aug 14, 2020

In Brief

A Phase 2 clinical trial evaluating Losartan, Allopurinol, and 1 other intervention for Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour) and Hypertension. Completed, enrolled 87 participants across 4 sites.

Detailed Summary

The purpose of this study is to determine if two medicines (allopurinol and losartan) can influence heart and blood vessel health compared to placebo in patients with sleep apnea who are using continuous positive airway pressure (CPAP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 11, 2012
Enrollment StartJun 1, 2012
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.0 years ago

Interventions

Losartandrug

Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.

Allopurinoldrug

Allopurinol 300 mg daily for 6 weeks

Placebodrug

Placebo capsule daily for 6 weeks